KDR and neoplasm: Endostar is an anti-angiogenic agent with multiple targets including the VEGF/VEGFR pathway and can enhance anti-tumor activities of some chemotherapy drugs and checkpoint inhibitors (Yao et al., 2017; Xue et al., 2022).